Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study

Hagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, Elias Jabbour, Partow Kebriaei, Michael Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl, Mary Beth Rios, Jorge Cortes, Luis Fayad, Robert Tarnai, Sa A. Wang, Richard Champlin, Anjali Advani, Susan O'Brien

Research output: Contribution to journal › Article › peer-review

342 Scopus citations

Fingerprint

Dive into the research topics of 'Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences